Medicare drug price negotiations: The first drug list is here!
The list of ten drugs for Medicare price negotiation has been published! What do we know about these Medicare "blockbusters"? And how are drugmakers taking the news? More
What’s the tea on 340B?
If you want to see an epic battle between hospitals and pharma, look no further than the 340B drug discount program. Why is this program so controversial, and what do new studies show about its effectiveness? More
Defining “better”: A look at the new Alzheimer’s drugs
Unlike its predecessor drug aducanumab, lecanemab actually showed a statistically significant difference in slowing cognitive decline in its clinical trial. But can the drug improve patients’ quality of life? More
When it comes to prescription drugs, are we getting what we pay for?
Two recent analyses of expensive medications indicate that many drugs are being priced above their actual clinical benefit. More
After decades of profiteering, insulin manufacturer finally cuts the price
Insulin manufacturer Eli Lilly announced that it would be cutting the list price of its generic insulin products significantly. This move comes after decades of advocacy work by patients and clinicians alike, including our sister organization the Right Care Alliance. What does this tell us about the drug pricing landscape? More
Power to the People: How a single tweet could reignite a movement
With $8 and 9 words, one internet troll is forcing insulin manufacturers to answer the question of why the drug is so unaffordable More
Debunking pharma’s spin on racial equity
What could be a fruitful conversation on racial equity is being co-opted by pharmaceutical companies to sell unproven drugs. More
1.3 million Americans forced to ration insulin, new study estimates
Skipping doses, intentionally undermedicating, not eating - these are all measures 1.3 million Americans are forced to take to keep their insulin costs down. More
Balancing hope and uncertainty: The controversy behind the new ALS drug
The reasoning behind this decision has to do with a complex bioethical question - if there is the potential to treat a previously untreatable disease with a new pharmaceutical, but the consequences are unknown, do you prescribe the drug? Is the unknown enough to deny patients hope? More
A win for Medicare patients and their wallets
The Inflation Reduction Act allows Medicare to negotiate drug prices and cap insulin costs...but only for Medicare enrollees. More
The Cerebral scandal brings ADHD overprescription into the spotlight
A telehealth company's downfall sheds light on the overprescription of stimulants to ADHD patients More
Why access to Aduhelm won’t improve health equity
After CMS restricted access to Aduhelm, Biogen and the Alzheimer's Association called the decision discriminatory. Here's why we're skeptical... More
What’s in the Congressional drug pricing report?
A recently-released Congressional committee report on drug prices reveals some outrageous business practices by pharma -- here's what they found. More
How a pharma-led campaign to lower a diabetes treatment target put seniors at risk
A recent Reuters investigation found that a campaign to lower the A1c target for diabetes was driven largely by pharmaceutical companies, to create a bigger market for their new blood sugar-lowering drugs. More
High-priced cancer drugs are driving pharma revenue
Has pharma cracked the secret code to profit through cancer drugs? A recent study takes a closer look at the impact of cancer drug prices on pharma revenues. More
Drug advertisements that scare
Despite larger health threats consuming the nation this year, pharma did not let up on their fear-mongering advertisements. Check out a few of the scariest-- if you dare! More
Is the price of remdesivir too high or too low?
Experts weigh in on the recently revealed price of Covid-19 drug remdesivir. More
Remdesivir report sparks more debate on drug price value
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
Are high drug prices buying us the most effective treatments?
The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More
What we lose by promoting unproven Covid-19 remedies
Breaking down the flawed logic of "What do we have to lose?" when it comes to untested Covid-19 treatments. More